----item----
version: 1
id: {74A611DD-8C05-4C76-8150-0B7E8E8A9F51}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/02/04/Inovio MedImmune partner under 45m DARPA Ebola contract
parent: {71B77356-F6BE-4338-8E8E-DDD3D21DC0D9}
name: Inovio MedImmune partner under 45m DARPA Ebola contract
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 00a9557b-cdcb-4557-8386-8311de94e8c7

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 57

Inovio, MedImmune partner under $45m DARPA Ebola contract
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 55

Inovio MedImmune partner under 45m DARPA Ebola contract
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 2327

<p>Shares of Inovio Pharmaceuticals got a 8.6% boost on 8 April on the news the firm was named the prime contractor by the US Defense Advanced Research Projects Agency (DARPA) to lead a consortium of companies and academic researchers tapped to develop multiple treatment and prevention approaches against Ebola &ndash; a disease that has infected more than 25,500 people in the current outbreak in West Africa, killing over 10,500.</p><p>DARPA, which is part of the US Department of Defense, awarded the consortium $21m under the contract, which has the potential to grow to $45m.</p><p>Inovio is collaborating on the contract with AstraZeneca unit MedImmune and GeneOne Life Sciences and its manufacturing subsidiary VGXI.</p><p>Researchers from the University of Pennsylvania, Emory University and Vanderbilt University also are partnering on the project, which will involve developing a DNA-based monoclonal antibody (dmAb) which is intended to be designed and manufactured expediently on a large scale using common fermentation technology is thermal-stable and may provide more rapid therapeutic benefit.</p><p>The partners also plan to develop and test a highly potent conventional protein-based therapeutic mAb.</p><p>The funds also will back further development of Inovio's experimental DNA-based vaccine against Ebola.</p><p>The company said the first patient is expected to be dosed with the vaccine in the second quarter. </p><p>In preclinical testing, the vaccine protected 100% of animals from death and sickness after being exposed to a lethal dose of the Ebola.</p><p>Inovio noted that it already is developing dMAb products against influenza and antibiotic-resistant bacteria as a subcontractor under a separate DARPA funded grant.</p><p>The new DARPA funds are expected to cover the costs for preclinical development of the dMAb products and the protein mAb candidates. The grant also is intended to cover the costs of the GMP manufacturing and the Phase I study with the three product candidates. </p><p>MedImmune will manufacture the protein mAbs under the contract, while the Inovio-GeneOne/VGXI team will manufacture the DNA-based products. </p><p>The academic partners are leading Ebola research and medical centers on the discovery efforts for the highly potent anti-Ebola mAbs. </p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 436

<p>Shares of Inovio Pharmaceuticals got a 8.6% boost on 8 April on the news the firm was named the prime contractor by the US Defense Advanced Research Projects Agency (DARPA) to lead a consortium of companies and academic researchers tapped to develop multiple treatment and prevention approaches against Ebola &ndash; a disease that has infected more than 25,500 people in the current outbreak in West Africa, killing over 10,500.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 55

Inovio MedImmune partner under 45m DARPA Ebola contract
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150204T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150204T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150204T000000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028370
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 57

Inovio, MedImmune partner under $45m DARPA Ebola contract
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

pdfNewsLetter
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357635
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042327Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

00a9557b-cdcb-4557-8386-8311de94e8c7
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042327Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
